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Elevated Fibroblast growth factor 
21 (FGF21) in obese, insulin 
resistant states is normalised by 
the synthetic retinoid Fenretinide 
in mice
Nicola Morrice1,2, George D. Mcilroy1, Seshu R. Tammireddy3, Jennifer Reekie1, 
Kirsty D. Shearer1, Mary K. Doherty3, Mirela Delibegović1, Phillip D. Whitfield3 & 
Nimesh Mody1
Fibroblast growth factor 21 (FGF21) has emerged as an important beneficial regulator of glucose and 
lipid homeostasis but its levels are also abnormally increased in insulin-resistant states in rodents 
and humans. The synthetic retinoid Fenretinide inhibits obesity and improves glucose homeostasis 
in mice and has pleotropic effects on cellular pathways. To identify Fenretinide target genes, we 
performed unbiased RNA-seq analysis in liver from mice fed high-fat diet ± Fenretinide. Strikingly, 
Fgf21 was the most downregulated hepatic gene. Fenretinide normalised elevated levels of FGF21 
in both high-fat diet-induced obese mice and in genetically obese-diabetic Leprdb mice. Moreover, 
Fenretinide-mediated suppression of FGF21 was independent of body weight loss or improved hepatic 
insulin sensitivity and importantly does not induce unhealthy metabolic complications. In mice which 
have substantially decreased endogenous retinoic acid biosynthesis, Fgf21 expression was increased, 
whereas acute pharmacological retinoid treatment decreased FGF21 levels. The repression of FGF21 
levels by Fenretinide occurs by reduced binding of RARα and Pol-II at the Fgf21 promoter. We therefore 
establish Fgf21 as a novel gene target of Fenretinide signalling via a retinoid-dependent mechanism. 
These results may be of nutritional and therapeutic importance for the treatment of obesity and type-2 
diabetes.
Fibroblast growth factor (FGF) 21 is a predominantly liver derived hormone and is being investigated as an 
anti-obesity/anti-diabetes therapy1. FGF21 binds cognate receptors FGFR and β -klotho, which are expressed at 
high levels in adipose tissue, to mediate its metabolic effects including control of lipid metabolism, body weight 
and glucose homeostasis1,2. Hepatic Fgf21 expression is increased by stimuli such as fasting, protein/amino acid 
restriction and fructose ingestion via a range of transcription factors, including peroxisome proliferator-activated 
receptor-alpha (PPARα ) and carbohydrate response-element binding protein (ChREBP) 13–5.
Circulating FGF21 levels are also elevated in states of metabolic stress in both rodents and humans and are 
positively correlated with body mass index and insulin resistance6. This has to led the hypothesis that a rise in 
serum FGF21 levels may be a predictor for metabolic syndrome and type-2 diabetes and that these may be states 
of relative “FGF21-resistance”7. Furthermore, diverse treatments to improve glycaemic control in humans can 
decrease elevated levels of FGF21 (e.g. with metformin, rosiglitazone, insulin, insulinotropic agents, bariatric 
surgery, lifestyle modification, fish oil supplements or exercise8–14). Thus, the biological role of FGF21 in obesity 
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and insulin resistance is still not fully explained and further understanding the regulation of FGF21 with the aim 
of modulating physiological levels maybe key in maximizing its therapeutic potential.
The synthetic retinoid 4-hydroxy(phenyl)retinamide (Fenretinide, FEN) is widely studied as a cancer thera-
peutic due to its favourable toxicological profile and is currently undergoing phase II clinical trials for treatment 
of insulin resistance in obese humans with hepatic steatosis15,16. We have previously shown that FEN prevents 
obesity and improves insulin sensitivity in both high fat diet (HFD)-fed male and female mice17–19. FEN acts via 
several different mechanisms including induction of retinoid signalling, increased hepatic lipid oxidation and 
inhibition of the final step of ceramide biosynthesis in multiple tissues to exert its metabolic effects20–22. FEN 
can also directly inhibit gene expression of the satiety hormone leptin and reduce serum levels in mice, but does 
not have measureable effects on food intake or energy expenditure17,18. The relationship between FEN and leptin 
signalling is not fully understood and it is not known whether FEN can modulate Fgf21 levels.
To further understand the signalling mechanisms of FEN, we performed RNA-seq analysis in liver from 
FEN-treated mice fed a HFD, which we had previously characterised18,22. Interestingly, Fgf21 was the gene most 
downregulated by FEN treatment. We therefore further tested the potential role of FEN in regulating hepatic 
Fgf21 in mouse models of diet and genetically-induced obesity and in wild-type animals.
Results
Hepatic Fgf21 is down regulated in HFD-fed mice receiving Fenretinide treatment. To identify 
targets of FEN signalling, RNA-seq analysis was performed in liver from C57BL/6 mice fed a HFD ± 0.04% FEN 
for 20 weeks. Representative mice (n = 4) from the whole cohort were selected based on the extensive pheno-
typing performed previously (data in Supplementary Table S1)18. Chronic FEN treatment resulted in significant 
upregulation of 377 genes and 487 were significantly downregulated (Fig. 1a).
The most upregulated genes were classic retinoid targets (cytochrome P450-type enzyme Cyp26a1, transcrip-
tion factor homeobox D4, Hoxd4 and metalloprotease Adam11) which were induced between 6.7 and 68-fold 
(Fig. 1a). The most significantly downregulated gene was carnitine acyltransferase (Crat) whilst, Fgf21 was the 
most downregulated gene, repressed 5.4-fold. Both of these genes are established PPARα targets involved in 
control of lipid metabolism3,23.
To determine whether FEN can oppose PPARα signalling, we also performed RNA-seq analy-
sis in liver from mice fed a HFD ± FEN for 7 days, which had also been previously characterised (data in 
Supplementary Table S1)18. Acute FEN treatment resulted in significant upregulation of several classic retinoid 
target genes and Fgf21 trended to be downregulated. However, FEN treatment did not change the expression of 
PPARα target genes or target genes of other transcription factors identified as having a role in inducing FGF21, 
e.g. ChREBP1 (Table 1)3,4,24,25.
Gene expression analysis in mice from the whole cohort (n = 7–8), including chow-fed lean animals, con-
firmed the decrease in Fgf21 expression in long-term treated mice and FEN also completely normalised elevated 
serum FGF21 levels (Fig. 1b). In mice receiving the acute diet intervention (HFD ± FEN for 7 days), HFD feeding 
did not increase Fgf21, however FEN decreased FGF21 expression and serum levels more than 50% below normal 
levels (Fig. 1c). Thus, FEN is able to inhibit Fgf21 expression both chronically in obese mice and more acutely in 
lean mice, without inducing parallel changes to known major regulators of hepatic Fgf21.
Fenretinide inhibits Fgf21 expression and improves glucose homeostasis without preventing 
weight gain in Leprdb genetically obese mice. To investigate the relationship between FEN and leptin 
signalling and determine effects on FGF21 levels in non-diet-induced obesity, we used the Leprdb genetic mouse 
model. Unlike in HFD mice, FEN did not inhibit rapid weight gain in Leprdb mice fed a 10% fat diet (Fig. 2a). FEN 
did decrease fasting hyperglycaemia and markedly attenuated glucose intolerance in Leprdb mice (Fig. 2b,c), in 
association with increased serum insulin (Fig. 2d) and increased pancreatic islet mass (Fig. 2e). Thus, FEN can 
improve glucose homeostasis independent of leptin signalling.
Hepatic expression and circulating levels of FGF21 were elevated in Leprdb mice but were completely normal-
ised by FEN treatment (Fig. 2f). FEN also suppressed the elevation of Fgf21 in perigonadal white adipose tissue 
(PG-WAT) but had no effect on the downregulation of Fgfr1 or β-klotho (Fig. 2g). Several PG-WAT metabolic 
genes (e.g. Pparγ and Glut4) were markedly downregulated in Leprdb mice. FEN co-ordinately increased the 
expression of these genes to levels similar to those measured in lean mice and also normalised the elevated expres-
sion of PG-WAT Rbp4 (Table 2).
FEN strongly increased hepatic expression of classic retinoid target genes, as expected (Table 2). FEN had 
no effect on many genes, circulating factors and metabolites known to have a key role in the control of appetite, 
adiposity, gluconeogenesis, macrophage infiltration or inflammation (Table 2).
Previous work has shown that FEN treatment results in alterations in ceramide and dihydroceramide levels in 
HFD obese mice, in association with improvements in glucose homeostasis and insulin sensitivity20,22. To deter-
mine whether FEN could have the same effect in genetically-obese mice, lipid analysis was performed in liver 
tissue from Leprdb mice. A number of ceramide species elevated in Leprdb mice were partially decreased by FEN 
treatment, including C18:0, C20:0 and C22:0 (Fig. 2h). With regards to the immediate precursor to ceramide in its 
biosynthetic pathway, FEN treatment also resulted in an increase in dihydroceramides, seven out of nine species 
measured (Fig. 2i), and increased the ratio of dihydroceramide to ceramide (Fig. 2j). Inhibiting de novo hepatic 
ceramide biosynthesis may be a mechanism by which FEN can improve insulin sensitivity and glycaemia in mice.
Thus, FEN improved glucose homeostasis without inhibiting obesity or decreasing tissue inflammation in 
Leprdb mice. FEN strongly modulated retinoid and metabolic genes in adipose and liver and decreased produc-
tion of ceramide biosynthesis in liver. FEN also inhibited the elevation in hepatic and adipose Fgf21 induced by 
obesity and impaired glucose homeostasis in Leprdb mice, demonstrating that the effects of FEN on Fgf21 gene 
expression are common to both diet- and genetically-induced obesity.
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Fenretinide treatment inhibits hepatic Fgf21 expression in Alb-cre-Ptp1b−/− mice, independ-
ent of effects on glucose homeostasis. To test whether directly improving hepatic insulin sensitivity and 
glucose homeostasis in the background of HFD-induced obesity could lead to a reduction in FGF21 levels, we 
examined mice with a hepatocyte-specific knock-out of PTP1B. Ptp1bfl/fl (fl/fl) and hepatocyte-specific Ptp1b−/− 
(Alb-cre-Ptp1b−/−) male mice were fed HFD ± FEN for 17 weeks. As previously reported26,27, Alb-cre-Ptp1b−/− 
mice showed no difference in body weight compared to fl/fl controls. FEN inhibited weight gain and adiposity 
(data not shown) in many Alb-cre-Ptp1b−/− mice but this did not reach statistical significance (Fig. 3a).
Alb-cre-Ptp1b knock-out resulted in improved glucose homeostasis in both HFD+ /− FEN mice. 
Alb-cre-Ptp1b−/− mice fed HFD appeared to be the most glucose tolerant but this was not statistically signifi-
cant (Fig. 3b,c). Alb-cre-Ptp1b knock-out alone did not alter serum insulin (Fig. 3d) or leptin (Fig. 3e) levels but 
FEN treatment decreased both factors in each genotype. FEN also increased retinoid gene expression in both 
fl/fl and Alb-cre-Ptp1b−/− mice, but there was no effect on hepatic Rbp4 expression (Fig. 3f). Importantly, Fgf21 
expression and serum levels were similar in Alb-cre-Ptp1b−/− and fl/fl mice with HFD-induced obesity, but FEN 
strongly decreased FGF21 in both groups (Fig. 3g). Thus, hepatic Fgf21 levels are not decreased as a result of 
improved hepatic insulin signalling alone, thereby providing further evidence for a direct effect of FEN on hepatic 
Fgf21, unrelated to improved insulin sensitivity and glucose homeostasis. However, diverse treatments to improve 
glycaemic control in humans can decrease elevated levels of FGF21, so it is unclear if there is a direct relationship 
between glucose homeostasis and FGF21 levels.
Figure 1. Hepatic Fgf21 is down regulated in HFD-fed mice receiving Fenretinide treatment. (a) Volcano 
plot of DESeq2 analysis of liver RNA-seq from C57BL/6 mice fed HFD ± FEN for 20 weeks (FEN-HFD; n = 4 
mice per group). Grey circles denote significantly changed gene expression (− log10 adj. p value < 0.05); black 
circles denote gene expression unchanged. (b) Liver mRNA expression measured by qPCR and serum FGF21 
levels in mice fed chow (lean, n = 5), HFD (n = 7) or FEN-HFD (n = 8) for 20 weeks, following 5-hour fast. 
(c) as in (b) except diets were fed for 7 days: chow (lean, n = 5), HFD (n = 7) or FEN-HFD (n = 8). Liver gene 
expression was normalized to Hprt. Significant differences were determined by one-way ANOVA followed by 
post-hoc tests. Differences are marked *p < 0.05 vs lean or #p < 0.05 vs HFD.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:43782 | DOI: 10.1038/srep43782
Fenretinide inhibits hepatic Fgf21 and induces changes to gene expression in lean mice fed a 
normal-fat diet. Next, we tested whether FEN could decrease body weight, improve glucose homeostasis 
and decrease FGF21 levels in lean mice fed a normal-fat diet. FEN had no effect on body weight, food intake 
(Fig. 4a,b) or glucose tolerance (Fig. 4c) but altered retinoid gene expression in PG-WAT, with increased Rarβ and 
Cyp26a1 and decreased Rbp4 expression (Fig. 4d). FEN also increased hepatic Rarβ, Cyp26a1 and Crbp1 (Fig. 4e). 
Strikingly, FEN decreased hepatic Fgf21 and circulating protein levels in these mice (Fig. 4f). These results suggest 
that FEN can inhibit basal hepatic Fgf21 expression but cannot decrease body weight or improve glucose home-
ostasis under normal physiological conditions.
Mice with reduced RA synthesis have increased Fgf21 expression. To establish whether our find-
ings were retinoid dependent, we used mice lacking the retinol metabolising enzyme retinaldehyde dehydro-
genase 1 (Raldh1−/−; liver western blot Fig. 5a shows deletion), which have an approximately 70% reduction 
in normal RA levels28. Raldh1−/− mice showed decreased fat mass (Fig. 5b,c) and improved glucose tolerance 
(Fig. 5d) compared to controls. Raldh1−/− mice showed increased hepatic gene expression of Fgf21 but not circu-
lating levels (Fig. 5e). These data suggest that Fgf21 may be directly suppressed by retinoid-dependent signalling 
mechanisms.
Acute retinoid treatment results in inhibition of hepatic Fgf21 expression and RARα binding 
at the Fgf21 promoter is reduced with Fenretinide treatment. Since FEN is an activator of both 
retinoid- and non-retinoid signalling pathways, we tested whether Fgf21 could be directly inhibited by RA. RA 
and FEN both increased hepatic target genes Cyp26a1 and Rarβ in lean C57BL/6 mice as expected (Fig. 6a) and in 
parallel decreased hepatic gene expression and circulating levels of FGF21 at two hours post-injection (Fig. 6b,c).
A putative retinoic acid response element (RARE) was previously reported within the Fgf21 promoter region29. 
We confirmed the presence of this RARE by ChIP-qPCR and observed that 2-hour FEN treatment resulted in 
decreased RARα binding at this site (Fig. 6d). Furthermore, both RARα and polymerase (Pol) II binding were 
decreased at the Fgf21 RARE in mice chronically fed FEN-HFD, compared to HFD-fed mice (Fig. 6e). Binding 
of both RARα and Pol-II were increased at RARE 1 of Cyp26a1 (Fig. 6e), which is induced by retinoid signaling. 
Together, these results suggest that retinoid signalling has a direct inhibitory effect upon Fgf21 gene expression.
To test whether acutely blocking RAR signalling could prevent the retinoid-induced suppression of Fgf21, 
we performed experiments in mouse primary hepatocytes. Treatment with GW7647, a potent PPARα ago-
nist, led to the induction of Fgf21 and Cd36 (Supplemental Figure S1a). However, RA treatment did not lead 
to the induction of Rarβ or the suppression of Fgf21 in these cells (Supplemental Figure S1a). Strikingly, Rarα 
Gene Log2 fold change adj. p value q value
Transcription factors
 Mlxipl (ChREBP) + 0.123 0.301 1.000
 Nr1h3 (LXRα ) − 0.095 0.431 1.000
 Nr1c1 (PPARα ) + 0.040 0.786 1.000
 Nr1c3 (PPARγ ) + 0.419 1.000 1.000
 Nr1d1 (Rev-erbα ) − 0.261 0.254 1.000
ChREBP targets
 Gck − 0.378 0.046 0.894
 Pck1 + 0.410 1.000 1.000
 Elovl6 − 0.288 1.000 1.000
LXR targets
 Apoe − 0.211 0.198 1.000
 Fas − 0.072 0.648 1.000
 Cyp7a1 − 0.196 1.000 1.000
PPARα /PPARγ targets
 Acot1 + 0.448 1.000 1.000
 Ehhadh + 0.211 0.786 0.163
 Vnn1 + 0.496 0.094 0.094
 Cidec + 0.159 1.000 1.000
 Cd36 − 0.211 0.150 1.000
 Mogat1 + 0.088 0.723 1.000
Rev-erbα targets
 Arntl (BMAL1) + 0.060 0.786 1.000
 Per1 − 0.021 0.585 1.000
 Cry1 + 0.104 1.000 1.000
Table 1.  Hepatic expression of genes regulated by transcription factors that also regulate Fgf21. DESeq2 
analysis of liver RNA-seq of expression of transcription factors known to regulate Fgf21 and some of their key 
target genes in mice fed HFD (n = 4) vs HFD + 0.04% FEN (FEN-HFD, n = 4) for 7 days.
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Figure 2. Fenretinide inhibits Fgf21 expression and improves glucose homeostasis without preventing 
weight gain in Leprdb genetically obese mice. (a) Body weight of C57BL/6 lean mice on chow (lean, n = 8; 
error bars too small to be shown clearly) and C57BL/6 Leprdb mice on 10% fat (Leprdb, n = 7) or 10% fat diet  
+ FEN (FEN-Leprdb, = 7). (b) Glucose (1 mg/g body weight) Tolerance Test (GTT) and (c) AUC at week 4.  
(d) serum insulin levels at the end of the study, following a 5 h fast. (e) Representative photos of haematoxylin 
and eosin staining of pancreas sections (10x magnification) and quantification of pancreatic islet size (n = 3 
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gene expression was found to be more than 10-fold lower in mouse primary hepatocytes than in mouse liver 
tissue (Supplemental Figure S1b). Thus, we suggest that down-regulation of RAR-signalling can prevent the 
retinoid-induced suppression of Fgf21.
Discussion
FGF21 is an important regulator of lipid and glucose metabolism and is undergoing trials in humans to evaluate 
its efficacy as a treatment for obesity and type-2 diabetes3. However, circulating levels of FGF21 are elevated in 
obesity and insulin-resistant states, therefore it is not clear if attempts to (in)directly increase levels further will 
be of therapeutic benefit in humans8,11,14. We have now identified FGF21 as a novel retinoid-dependent target of 
FEN and thus found a novel direct way to normalise elevated levels in both diet- and genetically-induced obese 
states whilst, at the same time, improving metabolic dysfunction.
Many others have reported that diverse treatments to improve glycaemic control in humans can decrease ele-
vated levels of FGF21, e.g. with metformin, bariatric surgery or exercise8,9,12,14. Although the mechanism by which 
FGF21 is physiologically induced by fasting, protein restriction and sugar intake is relatively clear, the molecular 
pathway by which the paradoxical elevation of FGF21 occurs in metabolically dysregulated states is still unknown. 
We have shown that HFD-feeding itself does not directly induce hepatic FGF21, suggesting that chronic dysregu-
lation of lipid and glucose homeostasis is responsible for the elevation in obese-insulin-resistant states. Moreover, 
improving hepatic insulin sensitivity and glucose homeostasis in the background of HFD-induced obesity did 
not decrease FGF21 levels in mice lacking hepatic PTP1B. Thus, more research is required to fully understand the 
nutritional and pharmacological regulation of FGF21 in physiological and patho-physiological states.
There have been some studies into the negative regulation of FGF21 e.g. PGC-1α potentiates the repressive 
activity of Rev-Erbα in concert with recruitment of the corepressors NCoR2 and HDAC3 on the FGF21 promoter 
in primary hepatocytes24. Our data, that RARα binding is reduced by FEN treatment at the Fgf21 promoter, 
suggests that Fgf21 is also repressed by RAR-mediated signaling in vivo. LXR is also reported to inhibit FGF21 
via recruitment of HDAC325. It is therefore possible that RARα may function via a similar mechanism to inhibit 
Fgf21 expression. FEN treatment did not change the expression of Rev-Erbα or LXR target genes (Table 1).
Results from cultured cells have not provided clear evidence for a direct mechanism of retinoid-induced sup-
pression of Fgf21. Fgf21 was shown to be induced by RARβ signaling in human HepG2 cells29. We found that 
down-regulation of Rarα in mouse primary hepatocytes prevented the retinoid-induced suppression of Fgf21. It 
is likely that these irreconcilable results are due to the molecular and physiological differences between cultured 
cells and in vivo systems. Directly activating/blocking RAR signalling in mice via the portal circulation could be 
a more suitable method to test these findings in the future.
We and others have recently identified FEN as a potential safe treatment for diet-induced obesity and type-2 
diabetes in mice17–19,22. FEN can directly inhibit leptin gene transcription but does not have measureable effects 
on food intake or energy expenditure17,18. Here, we have established that FEN does not inhibit excess weight 
gain driven by hyperphagia and low energy expenditure due to disrupted leptin signalling in Leprdb mice. These 
findings suggest that FEN may interact with leptin signalling to inhibit adiposity, but it is unlikely that a direct 
link can be determined given the difference in potency of effects between FEN and leptin on these energy balance 
parameters.
In contrast to the lack of an anti-obesity effect in Leprdb mice, FEN decreased fasting hyperglycaemia and glu-
cose intolerance and increased pancreatic islet mass and circulating insulin. However, this result contrasts with 
our studies in HFD-obese mice where FEN decreased serum insulin in parallel with beneficial effects on adiposity 
and glucose homeostasis18 and to the results shown here in Alb-cre Ptp1b−/− HFD-fed mice, where FEN treat-
ment also resulted in decreased serum insulin. These results suggest that with the genetic loss of leptin-signalling, 
FEN may improve insulin sensitivity via a direct effect on the pancreas, perhaps mediated by RA signalling. 
Normally, leptin inhibits insulin secretion and biosynthesis to adapt glucose homeostasis to the amount of body 
fat. However, in obesity, a state of leptin resistance contributes to dysregulation of the adipo-insular axis and pro-
motes the development of hyperinsulinaemia30. Moreover, RA can induce pancreatic development and affect the 
function of pancreatic β -cells, thus RA signalling may be involved in complex cross-talk with insulin and leptin 
signalling in normal physiology and this may be impaired in pathophysiological states31.
However, in the more physiological model of HFD-induced obesity, the mechanism of FEN action to improve 
glucose homeostasis is more likely due to an effect on adipose tissue to normalise impaired mitochondrial fatty 
acid beta-oxidation and tricarboxylic acid flux22. We and others have already shown that FEN can inhibit the final 
step in ceramide synthesis through blockade of the enzyme dihydroceramide desaturase 1 in adipose tissue20,22. 
per group). (f) Hepatic gene expression and serum levels of FGF21. Gene expression was normalised to Nono. 
(g) PG-WAT gene expression, normalised to yWhaz. Significant differences were determined by one-way 
ANOVA followed by post-hoc tests or student’s t-test for PG-WAT Fgf21 FEN-Leprdb vs Leprdb and Leprdb vs 
lean groups and β-klotho FEN-Leprdb vs Leprdb and Leprdb vs lean groups. Differences are marked *p < 0.05 vs 
lean or #p < 0.05 vs Leprdb. Quantification of ceramide (h) and dihydroceramide (i) species in liver. (j) Total 
liver levels of ceramide, dihydroceramide and the dihydroceramide/ceramide ratio. Significant differences 
were determined by one-way ANOVA followed by post-hoc tests or student’s t-test for ceramides: C18:0 FEN-
Leprdb vs Leprdb and FEN-Leprdb vs lean groups, C20:0 FEN-Leprdb vs Leprdb and FEN-Leprdb vs lean groups, 
C24:1 FEN-Leprdb vs Leprdb groups; dihydroceramides: C16:0 FEN-Leprdb vs Leprdb and Leprdb vs lean groups, 
C18:0 FEN-Leprdb vs Leprdb and Leprdb vs lean groups, C20:1 FEN-Leprdb vs Leprdb groups, C20:0 Leprdb vs 
lean groups, C24:0 FEN-Leprdb vs lean and Leprdb vs lean groups. Differences are marked *p < 0.05 vs lean or 
#p < 0.05 vs Leprdb.
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Here, we have now shown that ceramide synthesis is also blocked by FEN in liver in a genetic model of severe obe-
sity and insulin resistance. Excess levels of ceramides directly mediate impaired insulin signalling (via inhibition 
of Akt phosphorylation and dysregulation of mitochondrial fatty acid oxidation32,33). Thus, FEN may improve 
glucose homeostasis in mice via decreased ceramide accumulation and normalisation of metabolic flux in adi-
pose, liver and muscle, and/or metabolic flux between these insulin-sensitive tissues, independent of effects on 
the regulation of FGF21. Further data analysis of our RNA-seq data may reveal the pathways that are altered in 
association with the beneficial effects of FEN-treatment.
Gene Lean Leprdb FEN-Leprdb
Adipose: metabolic genes
 C/ebpα 1.00 ± 0.13 0.52 ± 0.05* 0.89 ± 0.19
 Chrebp1 1.00 ± 0.14 0.40 ± 0.07* 0.65 ± 0.10*
 Fas 1.00 ± 0.23 0.26 ± 0.03* 0.58 ± 0.14#
 Glut4 1.00 ± 0.13 0.36 ± 0.06* 0.63 ± 0.14
 Insulin receptor 1.00 ± 0.12 0.32 ± 0.04* 0.41 ± 0.08*
 Pparγ 1.00 ± 0.14 0.52 ± 0.09* 0.83 ± 0.19
 Scd1 1.00 ± 0.14 0.55 ± 0.06* 0.69 ± 0.06*
Adipose: retinoid genes
 Crbp1 1.00 ± 0.28 0.81 ± 0.17 1.07 ± 0.37
 Raldh1 1.00 ± 0.26 0.54 ± 0.13 0.65 ± 0.18
 Rarγ 1.00 ± 0.16 0.37 ± 0.09* 0.56 ± 0.11*
 Rbp4 1.00 ± 0.38 3.61 ± 0.99* 0.88 ± 0.46#
Adipose: adipokine genes
 Adiponectin 1.00 ± 0.18 0.22 ± 0.06* 0.21 ± 0.03*
 Leptin 1.00 ± 0.24 2.30 ± 0.83 1.49 ± 0.39
 Resistin 1.00 ± 0.18 0.19 ± 0.06* 0.11 ± 0.02*
Adipose: inflammation genes
 Cd11b 1.00 ± 0.15 3.34 ± 0.95* 2.98 ± 0.54*
 F4/80 1.00 ± 0.32 24.47 ± 5.66* 22.91 ± 6.16*
Liver: retinoid genes
 Crbp1 1.00 ± 0.15 1.75 ± 0.27* 22.26 ± 10.98*,#
 Cyp26a1 1.00 ± 0.11 0.31 ± 0.07* 47.77 ± 3.13*,#
 Lrat 1.00 ± 0.09 2.70 ± 0.29* 3.41 ± 0.36*
 Rbp4 1.00 ± 0.09 1.98 ± 0.20* 1.30 ± 0.13*,#
 Rarβ 1.00 ± 0.14 3.19 ± 0.47* 8.79 ± 1.02*,#
Liver: inflammation genes
 Cd11b 1.00 ± 0.25 3.12 ± 1.32 3.32 ± 0.41*
 F4/80 1.00 ± 0.16 4.94 ± 1.78* 3.10 ± 1.05*
Hypothalamus genes
 Foxo1a 1.00 ± 0.18 0.43 ± 0.04* 0.52 ± 0.13*
 Melanocortin 4 receptor 1.00 ± 0.26 0.49 ± 0.06 0.37 ± 0.03*
 Npy 1.00 ± 0.15 1.61 ± 0.32* 1.85 ± 0.39
 Npy receptor 1.00 ± 0.22 0.62 ± 0.07 0.44 ± 0.05*
 Pomc 1.00 ± 0.12 0.16 ± 0.06* 0.22 ± 0.04*
 Ptp1b 1.00 ± 0.13 0.48 ± 0.06* 0.49 ± 0.06*
 Raldh2 1.00 ± 0.13 0.76 ± 0.08* 0.96 ± 0.21
 Stat3 1.00 ± 0.20 0.49 ± 0.04* 0.46 ± 0.08*
 Tgfβ1 1.00 ± 0.26 0.54 ± 0.07 0.56 ± 0.09
Serum leptin 5.60 ± 1.63 131.48 ± 3.34* 134.88 ± 6.09*
Liver triglycerides 8.34 ± 0.89 53.75 ± 5.40* 61.97 ± 9.73*
Table 2.  Gene expression, serum factors and metabolites in Leprdb mice. Relative mRNA in PG-WAT, 
liver and hypothalamus and serum factors and metabolites in lean or Leprdb mice+ /− FEN. Expression was 
normalised to Nono in liver or yWhaz in adipose and hypothalamus. Data are shown as mean ± SEM and 
significance determined by one-way ANOVA followed by post-hoc tests or student’s t-test for liver: Crbp1 Leprdb 
vs lean, Rbp4 FEN-Leprdb vs lean, Cd11b FEN-Leprdb vs lean and F4/80 FEN-Leprdb vs lean and Leprdb vs lean 
groups; PG-WAT: Scd1 Leprdb vs lean, Fas FEN-Leprdb vs Leprdb, Pparγ Leprdb vs lean, C/ebpα Leprdb vs lean, 
Fgf21 Leprdb vs lean, Rarγ FEN-Leprdb vs lean, Cd11b Leprdb vs lean, Fgf21 FEN-Leprdb vs Leprdb and Leprdb vs 
lean and β-klotho FEN-Leprdb vs lean and Leprdb vs lean groups; hypothalamus: Npy Leprdb vs lean, and Raldh2 
Leprdb vs lean groups. Differences are marked *p < 0.05 vs lean; #p < 0.05 vs Leprdb.
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Overall, the list of effects upon FEN treatment now includes suppressing the elevation of FGF21 in insulin 
resistant states. Since the pleotropic effects of FEN are all beneficial and not at all detrimental, our findings sug-
gest targeting the multiple molecular defects that are manifest with metabolic disease may be an achievable goal.
Methods
Animals. Experiments were approved by the University of Aberdeen Ethics Board and performed following 
UK Home Office licenses PPL60/3951 and PPL70/7911 under the Animals (Scientific Procedures) Act 1986. 
Male C57BL/6 mice fed HFD ± 0.04% FEN were previously reported (Supplementary Table S1)18,22. HFD used 
in respective mouse cohorts through-out this study contained 45% lard-based fat. Male C57BL/6 Leprdb and lean 
wild-type/heterozygous littermates were from Charles River (Edinburgh, UK). Mice were group-housed (2–3 
obese/8 lean mice per cage) with conditions as previously reported18. Male C57BL/6 Raldh1−/− and wild-type 
Figure 3. Fenretinide treatment inhibits hepatic Fgf21 expression in Alb-cre-Ptp1b−/− mice, independent 
of effects on glucose homeostasis. (a) Body weight of fl/fl male mice on HFD (fl/fl-HFD, n = 9) or HFD + 
FEN (fl/fl-FEN-HFD, n = 9) or hepatocyte-specific-Ptp1b−/− male mice on HFD (Alb-cre-Ptp1b−/−-HFD, 
n = 5) or FEN-HFD (Alb-cre-Ptp1b−/−-FEN-HFD, n = 7). (b) GTT (1 mg/g glucose) and AUC (c) at week 15. 
(d) Serum insulin and (e) serum leptin levels at the end of the experiment, following a 5-hour fast. (f) Hepatic 
gene expression of retinoid and metabolic genes, normalised to Hprt. (g) Hepatic mRNA expression and serum 
levels of FGF21. Significant differences were determined by two-way ANOVA followed by post-hoc tests or 
student’s t-test for GTT AUC Alb-cre-Ptp1b−/−-FEN-HFD vs fl/fl-HFD; Rarβ FEN-HFD (both fl/fl and Alb-cre-
Ptp1b−/−) vs fl/fl-HFD; Fgf21 FEN-HFD (both fl/fl and Alb-cre-Ptp1b−/−) vs fl/fl-HFD and FEN-HFD vs HFD 
in Alb-cre-Ptp1b−/−. Differences are marked *p < 0.05 vs fl/fl-HFD, #p < 0.05 vs Alb-cre-Ptp1b−/−-HFD or † vs 
fl/fl-FEN-HFD.
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mice were bred in-house and described previously18. Ptp1bfl/fl and albumin-cre-Ptp1b−/− mice with hepato-
cyte-specific deletion of protein tyrosine phosphatase (PTP)-1B
(Alb-cre-Ptp1b−/−) were previously generated26,27. Alb-cre-Ptp1b−/− mice were fed HFD ± FEN as previ-
ously reported for C57BL/6 mice18,22. In FEN-diet studies, both Leprdb and C57BL/6 mice were fed 10% fat diet 
(D12450B, Research Diets, New Brunswick, NJ). Lean controls, C57BL/6 mice for injection studies and Raldh1−/− 
mice were fed chow diet18. Glucose tolerance test (GTT) and fat mass measurements by Echo MRI or DEXA scan 
were performed as previously described5,18. GTT area under the curve was calculated using time zero glucose 
level for each mouse. Mice were killed following a 5 h fast (except for injection studies), tissues rapidly dissected, 
flash frozen in liquid nitrogen and stored at − 80 °C until further use.
Tissue and serum analysis. Tissue serum factors, liver triacylglycerols and gene expression were measured 
as previously described5. Most stable reference genes were selected by screening a panel of common reference 
genes with RefFinder34. Mouse primer sequences used for qPCR are listed in Supplementary Table S2. Pancreas 
tissues for IHC were rapidly dissected, fixed in formalin and embedded in paraffin wax using a Peloris II tis-
sue processor (Leica Biosystems, Milton Keynes, UK). Embedded tissue was cut into 4 μ M-thick sections and 
mounted onto glass slides. Tissue sections were dewaxed, stained with haematoxylin and eosin, and visualized 
using an Axioskop 40 microscope (Zeiss, Cambridge, UK). Islet area size was quantified using ImageJ software 
(NIH, Bethesda, MD, USA).
RNA sequencing. Total RNA was extracted from frozen liver using TriZOL reagent (Sigma Aldrich, Irvine, 
UK) to manufacturer’s instructions. RNA was purified using RNeasy miniprep kit (Qiagen, Manchester, UK) 
and quantified on a Bioanalyzer 2000 (Agilent Technologies, Edinburgh, UK). Ribosomal RNA was removed 
Figure 4. Fenretinide inhibits hepatic Fgf21 and induces changes to gene expression in lean mice fed a 
normal-fat diet. (a) Body weight of C57BL/6 mice on 10% fat diet (n = 10) or 10% fat + FEN (FEN-10% fat, 
n = 10). (b) Weekly food intake of mice during weeks 2–7. (c) GTT (2 mg/g body weight) at week 18. Student’s 
t-test was used to determine significant differences (none). Expression of retinoid target genes was measured 
in PG-WAT (d) and liver (e). Gene expression was normalized to the geomean of 18s, NoNo and yWhaz (PG-
WAT) or geomean of NoNo, yWhaz and β-actin (liver). (f) hepatic gene expression and serum levels of FGF21. 
Significant differences were determined by student’s t-test. Differences are marked *p < 0.05 vs control.
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from samples using the Ribo-Zero rRNA removal kit (Illumina, San Diego, CA, USA). Sequencing libraries were 
prepared using the TruSeq RNA Library Preparation Kit v2 (Illumina) following the low sample protocol, using 
1 μ g RNA. Libraries were sequenced on the NextSeq-500 Desktop sequencer platform (Illumina) with a 2 × 75 
paired-end read length giving 719 million raw reads (average depth 45 million reads per sample). Reads were fil-
tered using the FASTQ Toolkit v2.0.0 in the Illumina BaseSpace cloud computing environment to remove adapter 
sequences and reads with phred score < 20 or length < 20 bp35. Filtered reads were checked using FastQC before 
aligning with STAR 2.0 to the Mus musculus UCSC mm10 genome and differential expression measured using 
DESeq2 with default parameters36–40.
Quantification of liver dihydroceramides and ceramides. Extraction of liver lipids was performed 
according to the method described by Folch et al.41. Ceramides and dihydroceramides were isolated by solid 
phase extraction chromatography using C17:0 ceramide and C12:0 dihydroceramide (Avanti Polar Lipids, 
Alabaster, Al, USA) as internal standards. Samples were analysed by liquidchromatography–mass spectrometry 
(LC–MS) using a Thermo TSQ Quantum Ultra mass spectrometer (Thermo Scientific, Hemel Hempstead, UK), 
equipped with a heated electrospray ionisation (HESI) probe and coupled to a Thermo Accela 1250 UHPLC 
system. Samples were analysed in positive ion mode over the mass to charge (m/z) range 200–2000. The samples 
were injected on to a Kinetex C8 column (2.1 mm_100 mm, 2.6 μ m). Mobile phase A consisted of 90% (v/v) H2O2 
and 10% (v/v) acetonitrile with 0.1% (v/v) formic acid. Mobile phase B consisted of 90:10 isopropanol/acetonitrile 
with 0.1% (v/v) formic acid. The initial conditions for analysis were 80% B and the percentage of mobile phase 
B was increased to 100% over 15 minutes and held for 1 min before re-equilibration with the starting conditions 
for 4 min. All solvents were LC–MS grade (Fisher Scientific, Loughborough, UK). The raw LC–MS data were 
processed with Thermo Xcalibur v2.1 (Thermo Scientific) and concentration of ceramide and dihydroceramide 
molecular species determined by comparison to calibration curves generated with C16:0 and C24:1 standards 
(Avanti). Total ceramide and dihydroceramide concentrations were calculated from the summed concentrations 
of all the monitored molecular species. All values were normalised to the wet weight of liver.
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Figure 5. Mice with reduced RA synthesis have increased Fgf21 expression. (a) Representative immunoblot 
of hepatic RALDH1 levels from C57BL/6 wild type (n = 7 for whole group) and C57BL/6-Raldh1−/− mice (n = 8 
for whole group). (b) Body weight and fat mass (c) of all mice. (d) GTT (1 mg/g glucose) and AUC analysis at 
week 10. (e) Hepatic Fgf21 expression (normalized to Hprt) and FGF21 serum levels. Significant differences 
were determined by student’s t-test. Differences are marked *p < 0.05 vs wildtype.
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Immunoblotting and Chromatin Immunoprecipitation (ChIP). Tissue lysates were prepared and 
immunoblotting performed as described previously42,43. ALDH1A1 (RALDH1; Abcam; ab52492) and β -actin 
(Pierce Scientific; PA1-21176) primary antibodies were at 1/1000 dilution; peroxidase-conjugated goat-anti-rabbit 
secondary antibody (Anaspec; 28177) at 1/5000 dilution. ChIP was performed using the SimpleChIP kit (9002, 
Cell Signalling, Danvers, MA) with antibodies: RARα (C15310155, Diagenode) and Pol II (sc-3001, Santa Cruz).
Statistical analysis. Sequencing data was analysed with DESeq2 and presented as p values normalised for a 
false discovery rate of 0.05. All other data was analysed using Sigmaplot 13.0 and presented as mean ± SEM and 
compared using two-way or one-way ANOVA with post-hoc tests or student’s t-test as indicated.
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Figure 6. Acute retinoid treatment results in inhibition of hepatic Fgf21 expression and RARα binding 
at the Fgf21 promoter is reduced with Fenretinide treatment. C57BL/6 mice were on chow diet and ad 
libitum fed before a single injection of olive oil vehicle or 50 mg/kg RA or FEN for 2 hours, n = 8 for each 
group. (a) Hepatic gene expression of retinoid targets normalised to yWhaz. (b) Hepatic Fgf21 expression and 
(c) serum FGF21 levels. Significant differences were determined by one-way ANOVA followed by post-hoc 
tests or student’s t-test for Cyp26a1 FEN vs RA, Rarβ FEN vs vehicle, Fgf21 mRNA FEN vs vehicle and FGF21 
serum FEN vs vehicle. Differences are marked *p < 0.05 vs vehicle or #p < 0.05 vs RA. (d) ChIP-qPCR of RARα 
binding at the hepatic Fgf21 RARE in mice injected with vehicle or 50 mg/kg FEN for 2 hours (n = 2 IP’s from 3 
individual mice per group). IgG antibody was used to measure non-specific binding (IgG ab, n = 1). (e) ChIP-
qPCR of RARα and polymerase (Pol) II binding at the hepatic Fgf21 and Cyp26a1 RAREs in mice fed HFD or 
HFD + FEN (FEN-HFD) for 20 weeks (n = 1 IP from 4 individual mice per group). IgG antibody was used to 
measure non-specific binding (IgG ab). Significant differences were determined by student’s t-test. Differences 
are marked *p < 0.05.
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